Leflunomide Tillomed

Leflunomide, the active ingredient in Leflunomide Tillomed, is a disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients, where it modulates the immune response to reduce joint inflammation and help prevent structural damage.

GNH USA supplies Leflunomide Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Leflunomide is a disease-modifying antirheumatic drug used in the management of inflammatory arthritis.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriatic arthritis: alleviates joint symptoms and inhibits structural damage. Moderate to severe rheumatoid arthritis refractory to other DMARDs: provides an alternative therapeutic option.

Leflunomide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness or urge to vomit. - Alopecia: thinning or loss of hair. - Elevated liver enzymes: increased ALT/AST indicating hepatic stress.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure requiring monitoring. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Bone marrow suppression: neutropenia, anemia, or thrombocytopenia.

Before initiating therapy, several safety considerations should be observed. - Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential. - Liver function: assess baseline and monitor regularly during therapy. - Blood pressure: monitor for hypertension, especially in patients with cardiovascular risk. - Infection risk: evaluate for active infections before initiating treatment. - Vaccination: avoid live vaccines while receiving leflunomide. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Leflunomide can interact with several medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluoroquinolones): increase leflunomide exposure. - Hepatotoxic drugs (e.g., azathioprine, isoniazid): heightened risk of liver injury. - Methotrexate: additive bone marrow suppression and hepatotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Live vaccines: reduced efficacy and increased risk of adverse events. - Cholestyramine: can accelerate leflunomide clearance, lowering therapeutic levels.